DiaSorin

Healthy Q2 and H1; resulting in consecutive guidance upgrade

04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."

PDF page sample
Pages
69
Language
English
Published on
04/08/22
Download
You may also be interested by these reports :
12/09/25
DiaSorin appears to be making significant progress in the testing space. The launch of speciality tests, introduction of the Plex platform, and ...
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO